Compare SoFi Technologies Inc (SOFI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoFi Technologies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? SoFi Technologies Inc trades at $15.72 (market cap $20.16B), while State Street SPDR S&P Biotech ETF trades at $154.32 (market cap $10.11B). The key difference: SoFi Technologies Inc is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SoFi Technologies Inc for 60 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| SOFI | XBI | |
|---|---|---|
Market Cap | $20.16B | $10.11B |
Volume | 49,646,331 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $32.21 | $169.55 |
52-Week Low | $15.15 | $104.99 |
Typical Hold Time | 60 Days | 37 Days |
Enterprise Value | $20.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SoFi Technologies (SOFI) trades at $15.72, up 0.38% on the day, but remains near 52-week lows amid a bearish technical outlook. The company reported strong revenue growth, with 2025 revenue reaching $3.61 billion and net income of $481.32 million, though cash flow from operations remains negative. Analyst consensus is mixed with a $21.58 price target, but technical indicators signal caution.
SoFi's growth trajectory and improving profitability present long-term potential, but near-term risks include persistent negative operating cash flow, high valuation multiples, and sensitivity to interest rates. Execution on loan originations and stablecoin initiatives will be critical for stock performance.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
